炎症
秋水仙碱
下调和上调
细胞凋亡
先天免疫系统
癌症研究
化学
细胞生物学
信号转导
免疫系统
炎症体
细胞因子
免疫学
泡沫电池
微泡
细胞
受体
促炎细胞因子
治疗方法
医学
机制(生物学)
病态的
巨噬细胞
作者
Qi Chen,Yi Peng,Qian Zhong,Yubo Zhang,Liubing Hu,Guan-Yan Zhang,Yixian Xu,Peina Dong,Si Qin Shen,Jing‐Hao Wang,Zhiguo Wang,Huan‐Tian Zhang,Rong Zeng,Hao Wang
标识
DOI:10.1186/s12951-025-03840-x
摘要
Atherosclerosis (AS) is a chronic inflammatory disorder characterized by foam cell formation and persistent inflammation as central pathological drivers. Although colchicine (Col) exhibits potent anti-inflammatory activities, its clinical application is limited by a narrow therapeutic window. In the present study, we developed phosphatidylserine-exposing nanovesicles (Col@PSVs) that leverage the innate phagocytic capacity of macrophage-derived foam cells by presenting surface “eat-me” signals, thereby enabling targeted immune modulation. The synergistic collaboration between Col and PSVs allows low-dose Col to retain robust anti-inflammatory efficacy while mitigating dose-dependent toxicity. Mechanistically, Col@PSVs potently suppress CCR7-mediated NF-κB signaling activation in foam cells, leading to a marked downregulation of pro-inflammatory cytokine and disruption of inflammatory cascades. In ApoE−/− AS mouse models, Col@PSVs treatment significantly improved plaque stability and attenuated disease progression. These findings highlight the pivotal role of the CCR7/NF-κB signaling pathway in AS-associated inflammation and present a translational nanotherapeutic strategy with the potential to overcome the clinical limitations of Col.
科研通智能强力驱动
Strongly Powered by AbleSci AI